


IN THE SPECIFICATION:

 Following the last page of the specification as originally filed, please replace the Sequence Listing with the accompanying Substitute Sequence Listing.

Please replace sections 'a' and 'b' on page 24, lines 21-29, with the following:

a. CD4<sup>+</sup> T cell epitope used in MAG

PV (poliovirus) sequence 103-115: KLFVWVKITYKDT (SEQ ID NO:4)

-M5: NGKLIAYPIAVEALS (SEQ ID NO:5)

b. Example of "Universal" CD4<sup>+</sup> T cell epitopes

-TT (tetanus toxin) derived T cell epitope such as sequence 830-844:

QYIKANSKFIGITEL (SEQ ID NO:1) (Panina Bordignon, et al., 1989, Reece, et al., 1993)

-PADRE (Pan DR T Helper epitope): aKXVAAWTLKAAa (a = D-Ala, X = L-cyclohexyl-Ala) (SEQ ID NO:6) (Alexander, et al., 1994)

Please replace the paragraph on page 43, lines 21-26, with the following:

As shown in figure 8 the MAG synthesized is composed of a dendrimeric lysine core structure with four arms. Each arm is linked to a CD4<sup>+</sup> T cell epitope (PV peptide: KLFVWVKITYKDT (SEQ ID NO:4) sequence from the poliovirus type 1; (Lo-Man et al. (1996)) with a single  $\alpha$ -N-acetylgalactosamine-serine residue (Tn) at the NH<sub>2</sub> terminus [MAG:Tn-PV: (Ser( $\alpha$ -GalNAc)]<sub>4</sub>-K<sub>2</sub>-K- $\beta$ Ala; Bay et al. (1997))].

Please replace the Table on page 55 with the following Table:

**TABLEAU 3: STRUCTURE OF THE DIFFERENT GLYCOPEPTIDES**

STTTG <sub>6</sub> KG	STTGGGGGGKG (SEQ ID NO:17)
Tn <sub>3</sub> G <sub>6</sub> KG	S*T*T*GGGGGGKG (SEQ ID NO:18)
Tn <sub>3</sub> G <sub>6</sub> K(Biot)G	S*T*T*GGGGGGK(Biotine)G (SEQ ID NO:19)
KG <sub>4</sub> Tn <sub>3</sub> G <sub>3</sub>	KGGGS*T*T*GGG (SEQ ID NO:20)
PV	KLFAVWKITYKDT (SEQ ID NO:4)
Tn-PV	S*KLFAVWKITYKDT (SEQ ID NO:21)
Tn <sub>3</sub> -PV	S*T*T*KLFAVWKITYKDT (SEQ ID NO:22)
D-(Tn <sub>3</sub> )-PV	D-(S*)D-(S*)D-(S*)KLFAVWKITYKDT (SEQ ID NO:23)
Tn <sub>6</sub> -PV	(S*T*T*G) <sub>2</sub> KLFAVWKITYKDT (SEQ ID NO:24)
Tn <sub>3</sub> -TT	S*T*T*QYIKANSKIGITEL (SEQ ID NO:25)

Please replace the paragraph on page 68, lines 10-11, with the following:

(PV = KLFAVWKITYKDT (SEQ ID NO:4), M5 - NGKLIAYPIAVEALS (SEQ ID NO:5))

\*MAP:PV2 corresponds to the addition of STT unglycosylated aa added to the PV sequence